New York Department of Health

The reelection of former President Donald Trump and Republican gains in Congress raise questions about FDA regulation of life sciences products. Key areas to watch include new agency heads and priorities, potential decrease in federal oversight, reproductive rights, rescheduling of marijuana, supply chain policies, changing approaches to vaccines and novel treatments, additional momentum for OTC drugs, and FDA policies for digital health technologies.

Amprion secured $6M from a $15M Series B round to expand commercial reach and dementia research. Their diagnostics detect misfolded proteins for Parkinson’s, Lewy body, and Alzheimer’s. The FDA supports their tests for research and trials. The round was led by Formation Venture Engineering, with Eli Lilly and Series A investors. Amprion aims to revolutionize brain disease diagnosis through precision medicine.